About CorMedix
CorMedix is a company based in Bridgewater (United States) founded in 2006. CorMedix has raised $2.62 million across 3 funding rounds from investors including HHS. The company has 65 employees as of December 31, 2024. CorMedix has completed 1 acquisition, including Melinta Therapeutics.
- Headquarter Bridgewater, United States
- Employees 65 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cormedix Inc.
-
Annual Revenue
$43.47 M (USD)0as on Dec 31, 2024
-
Net Profit
-$17.93 M (USD)61.31as on Dec 31, 2024
-
EBITDA
-$21.9 M (USD)55.08as on Dec 31, 2024
-
Total Equity Funding
$2.62 M (USD)
in 3 rounds
-
Latest Funding Round
$274.47 K (USD), Grant
Aug 15, 2017
- Investors
-
Employee Count
65
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CorMedix
CorMedix is a publicly listed company on the NASDAQ with ticker symbol CRMD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of CorMedix
Unlock access to complete
Funding Insights of CorMedix
CorMedix has successfully raised a total of $2.62M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $274.47 thousand completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CorMedix
CorMedix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for CorMedix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CorMedix
CorMedix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Melinta Therapeutics.
Investment portfolio details for CorMedix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of bacterial ribosome-targeting drugs for MDR infections
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for CorMedix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - CorMedix
Detailed financials for CorMedix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cormedix Comparisons
Peer comparison for CorMedix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CorMedix
Detailed competitors of CorMedix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cormedix
Complete news archive for CorMedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CorMedix
CorMedix was founded in 2006 and raised its 1st funding round 3 years after it was founded.
CorMedix is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
CorMedix is a funded company, having raised a total of $2.62M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CorMedix is 65.
Annual revenue of CorMedix is $43.47M as on Dec 31, 2024.
CorMedix was founded in 2006 as a biopharmaceutical company based in Bridgewater, United States. Therapeutic products are in-licensed, developed, and commercialized to address cardiac, renal, and infectious diseases. Operations center on Neutrolin, a solution designed to prevent infection, thrombosis, and biofilm in catheters for oncology, hemodialysis, and intensive care patients. CE approval has been obtained in Europe, with distribution planned for the United States, Middle East, South America, and Africa.
Yes, CorMedix is publicly traded on NASDAQ under the ticker symbol CRMD.
CorMedix has made 1 acquisition, including Melinta Therapeutics.
CorMedix has 1 investor. Key investors include HHS.
The ticker symbol of CorMedix is CRMD on NASDAQ.